

Table S1. List of International Classification of Diseases, 10th revision, German Modification (ICD-10-GM) codes used to identify cases of traumatic brain injury (TBI), number and distribution of cases identified by each code.

ICD-10-GM Code		Description	N	%
S02	S020	Fracture of vault of skull	99	0.6
	S021	Fracture of base of skull	186	1.1
	S023	Fracture of orbital floor	536	3.2
	S027	Multiple fractures involving skull and facial bones	28	0.2
	S028	Fractures of other skull and facial bones	58	0.3
	S029	Fractures of skull and facial bones, part unspecified	14	0.1
S04	S04	Injury of optic nerve and pathways	1	0.0
S06	S060	Concussion	11,302	67.5
	S061	Traumatic cerebral oedema	16	0.1
	S062	Diffuse brain injury	259	1.5
	S063	Focal brain injury	575	3.4
	S064	Epidural haemorrhage	116	0.7
	S065	Traumatic subdural haemorrhage	2,051	12.2
	S066	Traumatic subarachnoid haemorrhage	1,128	6.7
	S068	Other intracranial injuries	282	1.7
	S069	Intracranial injury unspecified	83	0.5
S09	S09	Unspecified injury of head	16	0.1
Total			16,750	100

Table S2. List of Anatomical Therapeutical Chemical (ATC) codes used to identify dispensations of antidepressants (ADs)<sup>1</sup>.

ATC code	Description
TCA	
N06AA01	Desipramin
N06AA02	Imipramin
N06AA03	Imipraminoxid
N06AA04	Clomipramin
N06AA05	Opipramol
N06AA06	Trimipramin
N06AA07	Lofepramin
N06AA08	Dibenzepin
N06AA09	Amitriptylin
N06AA10	Nortriptylin
N06AA11	Protriptylin
N06AA12	Doxepin
N06AA13	Iprindol
N06AA14	Melitracen
N06AA15	Butriptylin
N06AA16	Dosulepin
N06AA17	Amoxapin
N06AA18	Dimetacrin
N06AA19	Amineptin
N06AA20	Noxiptilin
N06AA21	Maprotilin
N06AA23	Quinupramin
N06AA25	Amitriptylinoxid
SSRI	
N06AB02	Zimeldin
N06AB03	Fluoxetin
N06AB04	Citalopram
N06AB05	Paroxetin
N06AB06	Sertralin
N06AB07	Alaproclat
N06AB08	Fluvoxamin
N06AB09	Etoferidon
N06AB10	Escitalopram
NaSSA	
N06AX03	Mianserin
N06AX11	Mirtazapin
N06AX16	Venlafaxin
MAO	
N06AF01	Isocarboxazid
N06AF02	Nialamid
N06AF03	Phenelzin
N06AF04	Tranlylcypromin
N06AF05	Iproniazid
N06AF06	Iproclozid
N06AG02	Moclobemid
N06AG03	Toloxaton

NARI	
N06AX18	Reboxetin
N06AX09	Viloxazin
Herbal antidepressants	
N06AH01	Hypericum
N06AH10	Various
N06AP01	St. John's Wort
N06AP51	St. John's Wort, combinations
Other antidepressants	
N06AX01	Oxatriptan
N06AX02	Tryptophan
N06AX04	Nomifensin
N06AX05	Trazodon
N06AX06	Nefazodon
N06AX07	Minaprin
N06AX08	Bifemelan
N06AX10	Oxaflozan
N06AX12	Bupropion
N06AX13	Medifoxamin
N06AX14	Tianeptin
N06AX15	Pivagabin
N06AX17	Milnacipran
N06AX19	Gepiron
N06AX21	Duloxetine
N06AX22	Agomelatin
N06AX23	Desvenlafaxin
N06AX24	Vilazodon
N06AX26	Vortioxetin
N06AX27	Pipofezin

---

<sup>1</sup> Abbreviations: tricyclics (TCA), selective serotonin reuptake inhibitors (SSRI), selective serotonin-noradrenaline reuptake inhibitors (SSNRI), noradrenergic and specific serotonergic antidepressants (NASSA), noradrenaline reuptake inhibitors (NARI), monoamine oxidase inhibitors (MAO).



Figure S1. Definition of the different exposure periods in cases and in controls based on the interval between index date (ID) and the end of the most recent prior treatment episode.




Table S3. ICD-10 GM Codes used for the calculation of the “Charlson Comorbidity Index” according to Quan et al.<sup>23</sup>

Disease	ICD-10-GM codes
Myocardial infarction	I21x
Congestive heart failure	I099, I110, I130, I132, I255, I420, I425-I429, I43x, I50x, P290
Dementia	F00x-F03x, F051, G30x, G311
Chronic pulmonary disease	I278, I279, J40x-J47x, J60x-J67x, J684, J701, J703
Rheumatic disease	M05x, M06x, M315, M32x- M34x, M351, M353, M360
Mild liver disease	B18x, K700, K701-K703, K709, K713-K715, K717, K73x, K74x, K760, K762-K764, K768, K769, Z944
Moderate / severe liver disease	I850, I864, I982, K704, K711, K721, K729, K765-K767
Diabetes with chronic complication	E102, E103, E104, E105, E107, E112, E113, E114, E115, E117, E122, E123, E124, E125, E127, E132, E133, E134, E135, E137, E142, E143, E144, E145, E147
Paraplegia / hemiplegia	G041, G114, G801, G802, G81x, G82x, G830-G834, G839
Renal disease	I120, I131, N032, N033, N034, N035, N036, N037, N052, N053, N054, N055, N056, N057, N18, N19, N250, Z49, Z940, Z992
Any malignancy, incl. lymphoma and leukemia, except malignant neoplasm of skin	C00x-C26x, C30x-C34x, C37x-C41x, C43x, C45x-C58x, C60x-C76x, C81x-C86x, C88x, C90x-C97x
Metastatic solid tumor	C77x-C80x
HIV / AIDS	B20-B24x

Table S4. ICD-10 GM Codes used to identify co-morbidities.

Disease	ICD-10-GM codes
Myocardial infarction	I21x ,I22x, I23x, I241, I252x
Other coronary heart disease	I20x, I24x (excl. I241), I25x (excl. I252 and I255)
Atrial fibrillation	I48x
Other cardiac arrhythmias and conduction disorders	I44x, I45x, I460, I469, I47x-I49x, R000, R001, R008, T821, Z450, Z950
Valvular disorders and endocarditis	A520, I011, I05x-I08x, I091, I098, I33x-I39x, Q230-Q233, Z952-Z954
Pericardial disorders	I010, I092, I30x-I32x
Myocarditis	I102, I40x, I41x, I514
Peripheral vascular disease	I70x, I71x, I731, I738, I739, I771, I790, I792, K551, K558, K559, Z958, Z959
Hypertension	I10x-I13x, I15x
Pain	F454x, F6280, G43x, G44x, G50x, G52x, G53x, G54x, G55x, G56x, G57x, G58x, G59x, G58x, G59x, G60x, G61X, G62x, G63x, G64, M43x, M45x, M46x, M47x, M47x, M48x, M49x, M50x, M51x, M53x, M54x, M792x, M81x, M82x, M89x,
Dementia	F00x-F03x, F051, G30x, G311, G3182
Chronic pulmonary disease	J40x-J47x, J60x-J67x, J684, J701, J703
Pulmonary circulation disorders	I26x, I27x, I280, I288, I289
Rheumatoid arthritis, other arthropathies and connective tissue disorders	L940, L941, L942, M05x, M06x, M08x, M120, M123, M30x, M310-M313, M32x-M35x, M45x, M461, M468, M469
Liver insufficiency	B18x, I850, I864, I982, K70x, K71x, K72x, K74x, K76x, Z944
Parkinson's disease and movement disorders	G20x-G26x, R25x-R27x (excl. R263), R290, F95x, G10,
Depression	F32x, F33x, F341, F412, F432
Diabetes	E10x-E14x
Anxiety disorders	F40x-F41x
Bipolar disorder	F30x-F31x
Obsessive compulsive disorder	F42
Delirium	F05, F104, F114, F124, F134, F144, F154, F164, F174, F184, F194
Schizophrenia	F20x
Renal insufficiency	I120, I131, N18x, N19x, N250, Z490-Z492, Z940, Z992
Cancer	C00x-C26x, C30x-C34x, C37x-C41x, C43x, C45x-C58x, C60x-C76x- C80x, C81x-C85x, C88x, C90x-C97x
Obesity	E66x
Alcohol abuse	F10x, G312, G621, G721, I426, K292, K70x, K860, T51x, Z502,
Drug abuse	F11x-F19x
Smoking	F17x
Osteoporosis and other diseases of bone density and structure	M80x-M85x
Senility and nursing home residence /residential care	EBM 03001 or coded hospital discharge to a nursing home
Syncope and dizziness	R42, R55x, R296
Vision disorders	H25x, H26x, H40x, H42x, H53x, H54x
Infectious diseases	A00x-B99x, G00x-G07x, I00x-I02x, I301, I320, I33x, I38x, I400, J00x-J22x, J36x, J390, K35x, K37x, K570, K572, K574, K578, K61x, K630, K650, K659, K67x, K750, K751, K800, K803, K804, K810, K819, K830, L00x-L03x, L05x-L08x, M00x, M01x, M86x, N10x, N12x, N151, N30x, N341, N390, N41x, N45x, N70x-N77x
Hip or pelvis fracture	S32x, S720-S722
Other fractures	S223, S2231, S2232, S224x, S42x, S52x, S521x, S522x, S523x, S524, S525x, S526, S62x, S72, S82x, S92x, S430x-S433, S530, S531, S531x S630, S630x, S831X
Dyslipidemia	E78x

Table S5. Odds Ratio (OR) with 95% confidence interval (95% CI) of traumatic brain injury in current, recent and past users of individual antidepressants (AD)<sup>1</sup> compared with remote users of any AD. Treatment episodes estimated based on the dispensed DDDs.

	Cases (N= 16,750)		Controls (N= 1,673,320)		Matched OR <sup>2</sup> (95% CI)	Adjusted OR <sup>3</sup> (95% CI)
	N	%	N	%		
Remote use of any AD <sup>4</sup>	8,432	50.3	1,004,327	60.0	1.00 (- -)	1.00 (- -)
<b>TCAs</b>						
Doxepin						
Current use	121	0.72	13,720	0.82	0.61 (0.47 - 0.77)	0.74 (0.58 - 0.95)
Recent use	107	0.64	14,044	0.84	0.59 (0.43 - 0.80)	0.71 (0.52 - 0.96)
Past use	129	0.77	16,365	0.98	0.68 (0.50 - 0.93)	0.80 (0.59 - 1.10)
Amitriptyline						
Current use	435	2.60	36,877	2.20	1.60 (1.45 - 1.77)	1.41 (1.28 - 1.56)
Recent use	288	1.72	26,857	1.61	1.47 (1.31 - 1.66)	1.36 (1.20 - 1.53)
Past use	280	1.67	31,708	1.89	1.19 (1.06 - 1.35)	1.13 (1.00 - 1.28)
Opipramol						
Current use	207	1.24	26,617	1.59	1.05 (0.91 - 1.21)	1.06 (0.92 - 1.21)
Recent use	136	0.81	18,837	1.13	0.98 (0.83 - 1.17)	1.02 (0.86 - 1.21)
Past use	137	0.82	22,298	1.33	0.83 (0.70 - 0.98)	0.88 (0.74 - 1.05)
Trimipramine						
Current use	103	0.61	9,864	0.59	1.41 (1.16 - 1.71)	1.34 (1.10 - 1.64)
Recent use	92	0.55	11,276	0.67	1.11 (0.90 - 1.37)	1.10 (0.89 - 1.35)
Past use	91	0.54	15,177	0.91	0.81 (0.66 - 0.99)	0.83 (0.67 - 1.02)
<b>SSRIs</b>						
Sertraline						
Current use	362	2.16	19,068	1.14	2.55 (2.29 - 2.83)	1.84 (1.65 - 2.05)
Recent use	36	0.21	2,294	0.14	2.12 (1.53 - 2.95)	1.56 (1.12 - 2.18)
Past use	38	0.23	2,525	0.15	2.00 (1.45 - 2.76)	1.54 (1.12 - 2.13)
Citalopram						
Current use	2,223	13.27	113,732	6.80	2.64 (2.52 - 2.77)	1.92 (1.82 - 2.02)
Recent use	398	2.38	22,479	1.34	2.41 (2.18 - 2.67)	1.80 (1.62 - 1.99)
Past use	334	1.99	21,703	1.30	2.07 (1.85 - 2.31)	1.60 (1.43 - 1.79)
Paroxetine						
Current use	92	0.55	6,411	0.38	1.89 (1.54 - 2.33)	1.65 (1.34 - 2.03)
Recent use	20	0.12	1,248	0.07	2.12 (1.37 - 3.31)	1.90 (1.22 - 2.96)
Past use	14	0.08	1,477	0.09	1.25 (0.74 - 2.12)	1.17 (0.69 - 1.99)
Fluoxetine						
Current use	71	0.42	5,299	0.32	1.79 (1.41 - 2.26)	1.50 (1.18 - 1.90)
Recent use	20	0.12	1,034	0.06	2.59 (1.66 - 4.04)	2.17 (1.39 - 3.39)
Past use	18	0.11	1,120	0.07	2.14 (1.34 - 3.41)	1.98 (1.24 - 3.16)
Escitalopram						
Current use	190	1.13	9,886	0.59	2.60 (2.25 - 3.01)	1.83 (1.58 - 2.12)
Recent use	33	0.20	1,644	0.10	2.73 (1.93 - 3.86)	2.08 (1.47 - 2.95)
Past use	18	0.11	1,707	0.10	1.42 (0.89 - 2.26)	1.12 (0.70 - 1.79)
<b>NASSA</b>						
Mirtazapine						
Current use	833	4.97	76,968	4.60	1.46 (1.36 - 1.57)	1.05 (0.97 - 1.13)
Recent use	329	1.96	26,656	1.59	1.69 (1.51 - 1.88)	1.28 (1.15 - 1.44)
Past use	287	1.71	25,705	1.54	1.51 (1.34 - 1.70)	1.20 (1.07 - 1.36)
<b>SSNRI</b>						
Duloxetine						
Current use	212	1.27	10,889	0.65	2.57 (2.23 - 2.94)	1.89 (1.64 - 2.17)
Recent use	50	0.30	3,300	0.20	2.03 (1.54 - 2.69)	1.59 (1.20 - 2.10)
Past use	37	0.22	3,055	0.18	1.62 (1.17 - 2.25)	1.28 (0.92 - 1.77)
Venlafaxine						
Current use	271	1.62	13,419	0.80	2.63 (2.33 - 2.97)	1.88 (1.66 - 2.13)
Recent use	51	0.30	3,321	0.20	2.02 (1.53 - 2.66)	1.55 (1.17 - 2.05)
Past use	32	0.19	2,536	0.15	1.66 (1.17 - 2.35)	1.30 (0.92 - 1.85)

<sup>1</sup> Abbreviations: tricyclics (TCA), selective serotonin reuptake inhibitors (SSRI), selective serotonin-noradrenaline reuptake inhibitors (SSNRI), noradrenergic and specific serotonergic antidepressants (NASSA), noradrenaline reuptake inhibitors (NARI), monoamine oxidase inhibitors (MAO).

<sup>2</sup> Adjusted for age, sex and length of follow-up by matching.

<sup>3</sup> Model adjusted for myocardial infarction, other coronary heart disease, atrial fibrillation, other cardiac arrhythmias and conduction disorders, valvular disorders and endocarditis, pericardial disorders, myocarditis, peripheral vascular disease, hypertension, dementia, chronic pulmonary disease, pulmonary circulation disorders, rheumatic arthritis/ collagen vascular disease, liver disease, Parkinson's disease, other extrapyramidal and movement disorders, depression, diabetes, renal failure, cancer (except malignant neoplasm of skin), obesity, alcohol abuse, drug abuse, osteoporosis and other disorders of bone density and structure, syncope, dizziness and tendency to fall, vision disorders, dyslipidemia, bipolar disorders, schizophrenia, smoking, anxiety disorders, obsessive compulsive disorders, other movement disorders, pain, infectious diseases, delirium, insulin, antidiabetic medications, antithrombotic medications, cardiac glycosides, anti-arrhythmic medications, other antihypertensive medications, diuretics, vasodilators, beta-adrenergic agonists, calcium antagonists, ACE inhibitors, angiotensin II antagonists, lipid lowering medications, hormone therapy, glucocorticoids, anti-parkinson medications, respiratory medications, non-steroidal anti-inflammatory medications, antipsychotics, antiepileptic medications, anxiolytics, hypnotics and sedatives, muscle relaxants, number of medications (1 to 4; 5 to 8, 9 and more), hospitalized time ( $\leq 5\%$ ;  $> 5\%$ ), Charlson Comorbidity Index ( $\leq 2$ ;  $> 2$ ), nursing home residence.

<sup>4</sup> Reference category.



Table S6. Odds Ratio (OR) with 95% confidence interval (95% CI) of traumatic brain injury in current, recent and past users of antidepressants (ADs) compared with current use of TCAs.

Use of AD <sup>6</sup>		Matched OR <sup>2</sup> (95% CI)	Adjusted OR <sup>3</sup> (95% CI)
Current use of TCA <sup>1</sup>		1.00 (- -)	1.00 (- -)
SSRI			
	Current	1.93	1.82 - 2.05
	Recent	1.22	1.00 - 1.50
	Past	1.16	0.98 - 1.37
NASSA			
	Current	1.18	1.09 - 1.27
	Recent	1.14	0.93 - 1.39
	Past	1.05	0.88 - 1.26
SSNRI			
	Current	1.91	1.73 - 2.10
	Recent	1.22	0.81 - 1.83
	Past	0.93	0.63 - 1.37
MAO			
	Current	0.80	0.46 - 1.38
	Recent	3.04	0.97 - 9.52
	Past	1.28	0.32 - 5.16
NARI			
	Current	1.69	1.07 - 2.67
	Recent	1.56	0.39 - 6.32
	Past	0.57	0.08 - 4.07
Other AD			
	Current	1.57	1.25 - 1.98
	Recent	1.20	0.60 - 2.42
	Past	1.49	0.86 - 2.59
Multiple AD			
	Current	1.99	1.83 - 2.15
	Recent	1.22	0.58 - 2.58
	Past	1.14	0.70 - 1.87
Current switching use <sup>5</sup>		1.97	1.81 - 2.15

<sup>1</sup> Reference category.

<sup>2</sup> Adjusted for age, sex and length of follow up by matching.


<sup>3</sup> Model adjusted for myocardial infarction, other coronary heart disease, atrial fibrillation, other cardiac arrhythmias and conduction disorders, valvular disorders and endocarditis, pericardial disorders, myocarditis, peripheral vascular disease, hypertension, dementia, chronic pulmonary disease, pulmonary circulation disorders, rheumatic arthritis/ collagen vascular disease, liver disease, Parkinson`s disease, other extrapyramidal and movement disorders, depression, diabetes, renal failure, cancer (except malignant neoplasm of skin), obesity, alcohol abuse, drug abuse, osteoporosis and other disorders of bone density and structure, syncope, dizziness and tendency to fall, vision disorders, dyslipidemia, bipolar disorders, schizophrenia, smoking, anxiety disorders, obsessive compulsive disorders, other movement disorders, pain, infectious diseases, delirium, insulin, antidiabetic medications, antithrombotic medications, cardiac glycosides, anti-arrhythmic medications, other antihypertensive medications, diuretics, vasodilators, beta-adrenergic agonists, calcium antagonists, ACE inhibitors, angiotensin II antagonists, lipid lowering medications, hormone therapy, glucocorticoids, anti-parkinson medications, respiratory medications, non-steroidal anti-inflammatory medications, antipsychotics, antiepileptic medications, anxiolytics, hypnotics and sedatives, muscle relaxants, number of medications (1 to 4; 5 to 8, 9 and more), hospitalized time ( $\leq 5\%$ ;  $> 5\%$ ), Charlson Comorbidity Index ( $\leq 2$ ;  $> 2$ ), nursing home residence.

<sup>4</sup> Not calculated owing to cell with 0 cases.

<sup>5</sup> Current switching use: current use of one ATD class with recent use of a different ATD class.

<sup>6</sup> Abbreviations: tricyclics (TCA), selective serotonin reuptake inhibitors (SSRI), selective serotonin-noradrenaline reuptake inhibitors (SSNRI), noradrenergic and specific serotonergic antidepressants (NASSA), noradrenaline reuptake inhibitors (NARI), monoamine oxidase inhibitors (MAO).


Figure S2. Odds Ratio (OR) with 95% confidence interval (95% CI) of traumatic brain injury in current, recent and past users of antidepressants (ADs)<sup>1</sup> compared with remote users of any AD by age<sup>2</sup>.



<sup>1</sup> Abbreviations: tricyclics (TCA), selective serotonin reuptake inhibitors (SSRI), selective serotonin-noradrenaline reuptake inhibitors (SSNRI), noradrenergic and specific serotonergic antidepressants (NASSA), noradrenaline reuptake inhibitors (NARI), monoamine oxidase inhibitors (MAO). <sup>2</sup> The model did not converge in the group of age 85 years and above.

\*° Model adjusted for myocardial infarction, other coronary heart disease, atrial fibrillation, other cardiac arrhythmias and conduction disorders, valvular disorders and endocarditis, pericardial disorders, myocarditis, peripheral vascular disease, hypertension, dementia, chronic pulmonary disease, pulmonary circulation disorders, rheumatic arthritis/ collagen vascular disease, liver disease, Parkinson's disease, other extrapyramidal and movement disorders, depression, diabetes, renal failure, cancer (except malignant neoplasm of skin), obesity, alcohol abuse, drug abuse, osteoporosis and other disorders of bone density and structure, syncope, dizziness and tendency to fall, vision disorders, dyslipidemia, bipolar disorders, schizophrenia, smoking, anxiety disorders, obsessive compulsive disorders, other movement disorders, pain, infectious diseases, delirium, insulin, antidiabetic medications, antithrombotic medications, cardiac glycosides, anti-arrhythmic medications, other antihypertensive medications, diuretics, vasodilators, beta-adrenergic agonists, calcium antagonists, ACE inhibitors, angiotensin II antagonists, lipid lowering medications, hormone therapy, glucocorticoids, anti-parkinson medications, respiratory medications, non-steroidal anti-inflammatory medications, antipsychotics, antiepileptic medications, anxiolytics, hypnotics and sedatives, muscle relaxants, number of medications (1 to 4; 5 to 8, 9 and more), hospitalized time ( $\leq 5\%$ ;  $> 5\%$ ), Charlson Comorbidity Index ( $\leq 2$ ;  $> 2$ ), nursing home residence.


Figure S3. Odds Ratio (OR) with 95% confidence interval (95% CI) of traumatic brain injury in current, recent and past users of antidepressants (ADs) compared with remote users of any AD by sex.



<sup>1</sup> Abbreviations: tricyclics (TCA), selective serotonin reuptake inhibitors (SSRI), selective serotonin-noradrenaline reuptake inhibitors (SSNRI), noradrenergic and specific serotonergic antidepressants (NASSA), noradrenaline reuptake inhibitors (NARI), monoamine oxidase inhibitors (MAO).

\*\* Model adjusted for myocardial infarction, other coronary heart disease, atrial fibrillation, other cardiac arrhythmias and conduction disorders, valvular disorders and endocarditis, pericardial disorders, myocarditis, peripheral vascular disease, hypertension, dementia, chronic pulmonary disease, pulmonary circulation disorders, rheumatic arthritis/ collagen vascular disease, liver disease, Parkinson's disease, other extrapyramidal and movement disorders, depression, diabetes, renal failure, cancer (except malignant neoplasm of skin), obesity, alcohol abuse, drug abuse, osteoporosis and other disorders of bone density and structure, syncope, dizziness and tendency to fall, vision disorders, dyslipidemia, bipolar disorders, schizophrenia, smoking, anxiety disorders, obsessive compulsive disorders, other movement disorders, pain, infectious diseases, delirium, insulin, antidiabetic medications, antithrombotic medications, cardiac glycosides, anti-arrhythmic medications, other antihypertensive medications, diuretics, vasodilators, beta-adrenergic agonists, calcium antagonists, ACE inhibitors, angiotensin II antagonists, lipid lowering medications, hormone therapy, glucocorticoids, anti-parkinson medications, respiratory medications, non-steroidal anti-inflammatory medications, antipsychotics, antiepileptic medications, anxiolytics, hypnotics and sedatives, muscle relaxants, number of medications (1 to 4; 5 to 8, 9 and more), hospitalized time ( $\leq 5\%$ ;  $> 5\%$ ), Charlson Comorbidity Index ( $\leq 2$ ;  $> 2$ ), nursing home residence.

Figure S4. Odds Ratio (OR) with 95% confidence interval (95% CI) of traumatic brain injury in current, recent and past users of antidepressants (ADs)<sup>1</sup> compared with remote users of any AD, by depression<sup>2</sup>.



<sup>1</sup> Abbreviations: tricyclics (TCA), selective serotonin reuptake inhibitors (SSRI), selective serotonin-noradrenaline reuptake inhibitors (SSNRI), noradrenergic and specific serotonergic antidepressants (NASSA), noradrenaline reuptake inhibitors (NARI), monoamine oxidase inhibitors (MAO). <sup>2</sup> The model did not converge in the group without depression.

\*\* Model adjusted for myocardial infarction, other coronary heart disease, atrial fibrillation, other cardiac arrhythmias and conduction disorders, valvular disorders and endocarditis, pericardial disorders, myocarditis, peripheral vascular disease, hypertension, dementia, chronic pulmonary disease, pulmonary circulation disorders, rheumatic arthritis/ collagen vascular disease, liver disease, Parkinson's disease, other extrapyramidal and movement disorders, depression, diabetes, renal failure, cancer (except malignant neoplasm of skin), obesity, alcohol abuse, drug abuse, osteoporosis and other disorders of bone density and structure, syncope, dizziness and tendency to fall, vision disorders, dyslipidemia, bipolar disorders, schizophrenia, smoking, anxiety disorders, obsessive compulsive disorders, other movement disorders, pain, infectious diseases, delirium, insulin, antidiabetic medications, antithrombotic medications, cardiac glycosides, anti-arrhythmic medications, other antihypertensive medications, diuretics, vasodilators, beta-adrenergic agonists, calcium antagonists, ACE inhibitors, angiotensin II antagonists, lipid lowering medications, hormone therapy, glucocorticoids, anti-parkinson medications, respiratory medications, non-steroidal anti-inflammatory medications, antipsychotics, antiepileptic medications, anxiolytics, hypnotics and sedatives, muscle relaxants, number of medications (1 to 4; 5 to 8, 9 and more), hospitalized time ( $\leq 5\%$ ;  $> 5\%$ ), Charlson Comorbidity Index ( $\leq 2$ ;  $> 2$ ), nursing home residence.